Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Jun 6, 2017 (9 years ago)

Andropharm M1 Alpha

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Marketed without an approved NDA/ANDA: product label states it contains anabolic steroids.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

ANDROPHARM M1 ALPHA (Methyl-1-Etiocholenolol-Epietiocholanollone 20 mg) capsule, packaged in 60-count bottle, Amazon.com, UPC 6 42125 50292 4

Recalling firm
Andropharm, LLC
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1143-2017 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Andropharm, LLC

All 2017 recalls
Class I · High risk

Andropharm Sten Z

Marketed without an approved NDA/ANDA: product label states it contains anabolic steroids.

Terminated Unapproved drug Andropharm, LLC D-1142-2017

Other unapproved drug recalls from 2017

All unapproved drug recalls
Class III · Low risk

Gabapentin Oral Solution

CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.

Terminated Unapproved drug Akorn Inc D-0211-2018
Class III · Low risk

Meclizine hydrochloride tablets USP

Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.

Terminated Unapproved drug Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-122-06 D-0082-2018